Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms

Fineline Cube Apr 2, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Company Deals

BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development

Fineline Cube Aug 12, 2022

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...

Policy / Regulatory

China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties

Fineline Cube Aug 12, 2022

The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security...

Company Drug

Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer

Fineline Cube Aug 11, 2022

Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...

Deals Hospital

ByteDance Acquires Amcare Healthcare for USD1.5b via Xiaohe Health Unit

Fineline Cube Aug 11, 2022

ByteDance Ltd, the parent company of social media platforms TikTok and Douyin, has acquired Amcare...

Company Deals Legal / IP Policy / Regulatory

Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center

Fineline Cube Aug 11, 2022

The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China,...

Company Deals

United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion

Fineline Cube Aug 11, 2022

Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...

Company Medical Device

Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center

Fineline Cube Aug 11, 2022

US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...

Company Deals

Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D

Fineline Cube Aug 11, 2022

China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million)...

Drug

Zhaoke Ophthalmology Enrolls First Patient in ZKY001 Phase II TPRK Study

Fineline Cube Aug 11, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery

Fineline Cube Aug 11, 2022

Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...

Company Drug

LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM

Fineline Cube Aug 11, 2022

China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III...

Company Deals

Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million

Fineline Cube Aug 11, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...

Company Drug

Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study

Fineline Cube Aug 11, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...

Company Deals Drug

Everest Medicines’ Xerava NDA Accepted by Taiwan’s TFDA

Fineline Cube Aug 11, 2022

Everest Medicines (HKG: 1952) announced that its New Drug Application (NDA) for Xerava (eravacycline) for...

Company

China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises

Fineline Cube Aug 11, 2022

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...

Company Drug

HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study

Fineline Cube Aug 10, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...

Company Drug

NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review

Fineline Cube Aug 10, 2022

The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...

Company Drug

Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne

Fineline Cube Aug 10, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...

Company Policy / Regulatory

NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme

Fineline Cube Aug 10, 2022

The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing...

Posts pagination

1 … 617 618 619 … 645

Recent updates

  • Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms
  • China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035
  • Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms
  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms

Others

China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035

Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.